GRTXD · Galera Therapeutics, Inc.
$18.99
At close · Aug 3
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, it expects its existing cash and cash equivalents as of March 31, 2026 will not enable the Company to fund its operating expenses and capital expenditure requirements for more than one year after the date these consolidated financial statements are issued, and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$3.05B
Shares
160.43M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
$149.05M
+886.2%
FY2025
Diluted EPS
$128.00
+288.2%
FY2025
Operating Cash Flow
-$6.05M
+50.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $271K | $349K | $3.15M | $24.12M | $31.01M | $52.42M | $54.85M | $42.33M | $18.66M | |
| $5.46M | $5.69M | $11M | $22.84M | $20.21M | $20.95M | $15.71M | $8.36M | $5.59M | |
| — | $0 | $20K | $259K | $114K | $778K | $368K | — | — | |
| — | — | $0 | $2.31M | — | — | — | — | — | |
| -$2.23M | -$2.54M | -$20.16M | -$49.26M | -$51.23M | -$73.37M | -$70.55M | -$50.69M | -$24.26M | |
| — | $0 | $0 | $11.41M | $11.57M | $7.19M | $4.88M | $3.03M | $220K | |
| $220K | $248K | $554K | $1.6M | $506K | $32K | $1.17M | $1.82M | $606K | |
| — | $149.05M | -$19.16M | -$59.08M | -$62.29M | -$80.53M | -$74.23M | -$51.94M | -$23.9M | |
| — | $0 | -$203K | $0 | $70K | $0 | -$16K | -$9000 | -$223K | |
| $149.04M | $149.05M | -$18.96M | -$59.08M | -$62.22M | -$80.53M | -$74.22M | -$51.93M | -$23.68M | |
| $63.52M | $63.52M | -$18.73M | -$59.08M | — | — | -$74.22M | -$59.11M | -$29.59M | |
| — | — | -$18.96M | -$59.06M | -$62.23M | -$80.56M | -$74.24M | -$51.9M | -$23.67M | |
| USD/shares | — | $128.00 | -$68.00 | -$266.00 | — | — | — | — | — |
| USD/shares | — | $128.00 | -$68.00 | -$266.00 | — | — | — | — | — |
| shares | — | 492.52K | 273.17K | 222.75K | — | 128.95K | 124.35K | 18.13K | 1502.985 |
| shares | — | 492.52K | 273.17K | 222.75K | — | 128.95K | 124.35K | 18.13K | 1502.985 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.40×
EV/EBIT
—
Peer median 22.07×
P/E (TTM)
—
Peer median 16.98×
Peer medians compare against the 236 similar-size Biotechnology companies (of 545 listed).